HC Wainwright Has Weak Outlook for Altimmune FY2029 Earnings

Altimmune, Inc. (NASDAQ:ALT) – Stock analysts at HC Wainwright lowered their FY2029 earnings per share (EPS) estimates for Altimmune in a research note issued to investors on Monday, March 3rd. HC Wainwright analyst P. Trucchio now anticipates that the company will post earnings per share of $1.26 for the year, down from their previous estimate of $1.30. HC Wainwright currently has a “Buy” rating and a $12.00 target price on the stock. The consensus estimate for Altimmune’s current full-year earnings is ($1.35) per share.

Altimmune (NASDAQ:ALT) last posted its quarterly earnings results on Thursday, February 27th. The company reported ($0.33) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.01. Altimmune had a negative return on equity of 55.81% and a negative net margin of 199,076.92%. The company had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.00 million.

A number of other equities research analysts have also weighed in on the stock. William Blair assumed coverage on shares of Altimmune in a report on Friday, February 28th. They issued a “market perform” rating on the stock. Stifel Nicolaus initiated coverage on Altimmune in a research note on Wednesday, January 8th. They issued a “buy” rating and a $18.00 price target on the stock. Finally, UBS Group started coverage on Altimmune in a research report on Tuesday, November 12th. They set a “buy” rating and a $26.00 price objective for the company. Two investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Altimmune has an average rating of “Moderate Buy” and an average target price of $20.83.

Altimmune Stock Down 0.5 %

Shares of NASDAQ:ALT opened at $5.96 on Wednesday. Altimmune has a fifty-two week low of $5.28 and a fifty-two week high of $11.77. The firm’s 50 day moving average price is $6.78 and its 200 day moving average price is $7.19. The stock has a market cap of $423.91 million, a price-to-earnings ratio of -3.85 and a beta of 0.19.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in ALT. Bellevue Group AG boosted its holdings in shares of Altimmune by 43.9% in the third quarter. Bellevue Group AG now owns 863,660 shares of the company’s stock valued at $5,303,000 after acquiring an additional 263,660 shares during the period. Virtu Financial LLC acquired a new stake in Altimmune during the 3rd quarter worth $674,000. Barclays PLC grew its position in Altimmune by 93.0% during the 3rd quarter. Barclays PLC now owns 155,741 shares of the company’s stock worth $956,000 after purchasing an additional 75,064 shares during the last quarter. Charles Schwab Investment Management Inc. increased its stake in Altimmune by 2.3% in the third quarter. Charles Schwab Investment Management Inc. now owns 211,626 shares of the company’s stock valued at $1,299,000 after purchasing an additional 4,772 shares during the period. Finally, Stifel Financial Corp increased its stake in Altimmune by 77.4% in the third quarter. Stifel Financial Corp now owns 17,752 shares of the company’s stock valued at $109,000 after purchasing an additional 7,746 shares during the period. Hedge funds and other institutional investors own 78.05% of the company’s stock.

About Altimmune

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.